Effects of iron deprivation on multidrug resistance of leukemic K562 cells

Chemotherapy

Volumn 56, Issue 1, 2010, Pages 9-16

  Fang, Dingzhu ^a   Bao, Yixiao ^a   Li, Xiaobin ^b   Liu, Fang ^a   Cai, Kang ^a   Gao, Ju ^c   Liao, Qingkui ^c  

^a JIAOTONG UNIVERSITY   (China)

^b Gongli Hospital Pudong New Area   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Cell differentiation; EGR1; Iron deprivation; MDR

Indexed keywords

DAUNORUBICIN; DEFEROXAMINE; EARLY GROWTH RESPONSE FACTOR 1; FERROUS CHLORIDE; GLYCOPROTEIN P; IRON; IRON BINDING PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PHORBOL 13 ACETATE 12 MYRISTATE;

ARTICLE; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL LEVEL; CELL STRAIN K 562; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; IRON DEPLETION; IRON METABOLISM; LEUKEMIA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOFERRITINS; CHLORIDES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EARLY GROWTH RESPONSE PROTEIN 1; FERRIC COMPOUNDS; GENES, MDR; HUMANS; IRON; IRON CHELATING AGENTS; K562 CELLS; LEUKEMIA; P-GLYCOPROTEIN; PHORBOL ESTERS;

EID: 77950524950     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000287352     Document Type: Article

References (32)

1. Eskiocak U, Ieri OD, Kars MD, Biçer A, Gunduz U: Effect of doxorubicin on telomerase activity and apoptotic gene expression in doxorubicin-resistant and -sensitive MCF-7 cells: an experimental study. Chemotherapy 2008; 54: 209-216.
2. Perkins C, Kim CN, Fang G, Bhalla KN: Arsenic induces apoptosis of multidrug resistance human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-X(L). Blood 2000; 95: 1014-1022.
3. Dassow H, Lassner D, Remke H, Preiss R: Modulation of multidrug resistance in human leukemia cells with MDR1 -targeted antisense oligonucleotides using variable treatment schedules. Int J Clin Pharmacol Ther 2000; 38: 209-216.
4. Chen Y, Chen Z, Zhuo G, Hu J: Reversal of multidrug resistance of leukemia cell line in vitro by antisense phosphorothioate oligonucleotide (in Chinese). Chin J Intern Med 1999; 38: 373-376.
5. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-199.
6. Kars MD, Ieri OD, Gunduz U, Molnar J: Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines. Chemotherapy 2008; 54: 194-200.
7. Baccarani M, Damiani D, Michelutti A, Michieli M: Expression of multidrug resistance gene (MDR1) in normal hematopoietic cells. Blood 1993; 81: 3480-3481. (Pubitemid 23172937)
8. Broxmeyer HE: H-Fn: a regulatory cytokine that down-modulates cell proliferation. J Lab Clin Med 1992; 120: 367-369.
9. Rouault TA, Klausner RD: Posttranscriptional regulation of genes of iron metabolism in mammalian cells. Bio Chem 1996; 1: 494-499.
10. Weinberg ED: Iron therapy and cancer. Kidney Int 1999; 55(suppl 69):s131-s134.
11. Poljak-Blazi M, Kralj M, Hadzija MP, Zarković N, Zarković K, Waeg G: Involvement of lipid peroxidation, oncogene expression and induction of apoptosis in the antitumors activity of ferric-sorbitol-citrate. Cancer Biother Radiopharm 2000; 15: 285-293.
12. Halliday JW, Ramm GA, Powell LW: Cellular iron processing and storage: the role of ferritin, in iron metabolism in health and disease. Adv Exp Med Biol 1994; 356: 149-156.
13. Jia GC, Gao J, Liao QK, Li FY, Yuan LX, He B: Detection of the labile iron pool in leukemia cells and its significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006; 14: 468-470.
14. Dayani PN, Bishop MC, Black K, Zeltzer PM: Desferoxamine (DFO)-mediated iron chelation: rationale for a novel approach to therapy for brain cancer. J Neurooncol 2004; 67: 367-377.
15. Guo M, Song LP, Jiang Y, Liu W, Yu Y, Chen GQ: Hypoxia-mimetic agents desferrioxamine and cobalt chloride induce leukemic cell apoptosis through different hypoxia-inducible factor-1alpha independent mechanisms. Apoptosis 2006; 11: 67-77.
16. Noulsri E, Richardson DR, Lerdwana S, Fucharoen S, Yamagishi T, Kalinowski DS, Pattanapanyasat K: Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am J Hematol 2009; 84: 170-176.
17. McCoy C, Smith DE, Cornwell MM: 12-Otetradecanoylphorbol- 13-activation of the MDR1 promoter is mediated by EGR-1. Mol Cell Biol 1995; 15: 6100-6108.
18. Alcantara O, Kalidas M, Baltathakis I, Boldt DH: Expression of multiple genes regulating cell cycle and apoptosis in differentiating hematopoietic cells is dependent on iron. Exp Hematol 2001; 29: 1060-1069.
19. Tokura Y, Shikami M, Miwa H, Watarai M, Sugamura K, Wakabayashi M, Satoh A, Imamura A, Mihara H, Katoh Y, Kita K, Nitta M: Augmented expression of P-gp/multidrug resistance gene by all-trans retinoic acid in monocytic leukemic cells. Leuk Res 2002; 26: 29-36.
20. List AF: Multidrug resistance: clinical relevance in acute leukemia. Oncology (Williston Park) 1993; 7: 23-28, 32; discussion 32, 35-38.
21. Bates SE, Mickley LA, Chen YN, Richert N, Rudick J, Biedler JL, Fojo AT: Expression of multidrug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid induced differentiation. Mol Cell Biol 1989; 9: 4337-4344.
22. Osborn MT, Berry A, Ruberu MS, Ning B, Bell M, Chambers C: Phorbol ester induced MDR1 expression in K562 cells occurs independently of mitogen-activated protein kinase signaling pathways. Oncogene 1999; 18: 5756-5764.
23. Lei HY, Zhao XL: Clinical significance of NF-kappa B continual activity and expression of WT1 and MDR1 in acute nonlymphocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007; 15: 253-257.
24. Ortega R, Moretto P, Fajac A, Benard J, Llabador Y, Simonoff M: Quantitative mapping of platinum and essential trace metal in cisplatin resistant and sensitive human ovarian adenocarcinoma cells. Cell Mol Biol (Noisyle- Grand) 1996; 42: 77-88.
25. Juckett MB, Balla J, Balla G, Jessurun J, Jacob HS, Vercellotti GM: Ferritin protects endothelial cells from oxidized low density lipoprotein in vitro. Am J Pathol 1995; 147: 782-789.
26. Epsztejn S, Glickstein H, Picard V, Slotki IN, Breuer W, Beaumont C, Cabantchik ZI: Hferritin subunit overexpression in erythroid cells reduces the oxidative stress response and induces multidrug resistance properties. Blood 1999; 94: 3593-3603.
27. Wong IL, Chow LM: The role of Leishmania enriettii multidrug resistance protein 1 (LeMDR1) in mediating drug resistance is iron-dependent. Mol Biochem Parasitol 2006; 150: 278-287.
28. Yang DC, Elliott RL, Head JF: Gene targets of antisense therapies in breast cancer. Expert Opin Ther Targets 2002; 6: 375-385.
29. Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD, Kuo MT: Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 1996,271: 14981-14988.
30. Nair P, Muthukkumar S, Sells SF, et al: Early growth response-1 dependent apoptosis is mediated by P53. J Biol Chem 1997; 272: 20131-20138.
31. Dingzhu F, Qingkui L, Ju G, Xuanjun Y, Lixin Y, Guocun J: EGR-1 mRNA expression during 12-O-tetradecanoylphorbol-13-acetate- induced K562 cell differentiation. Chin J Pediatr 2004; 7: 495-498.
32. Dingzhu F, Xiaobin L, Qingkui L, Dabin W, Xiaoyu M, Hongbo C: K562 cell growth and differentiation and EGR1mRNA expression were affected by iron deprivation during TPA-induced K562 cell differentiation. Prog Mod Biomed 2006; 5: 14-18.